High-density lipoprotein modulates tumor-associated macrophage for chemoimmunotherapy of hepatocellular carcinoma
Source abstract
Abstract
Abstract Intratumoral abundance of alternatively activated macrophages (M2) in hepatocellular carcinoma (HCC) is associated with advanced stages, poor prognosis and failure of checkpoint blockade immunotherapy. In this work, we discover that synthetic high-density lipoproteins (sHDLs) preferentially deliver cargoes into M2 and Hepa1–6 HCC cells, based on which finding we create a functional sHDL containing esterase-responsive prodrugs of vadimezan and gemcitabine (VG-sHDLs). The VG-sHDLs induce the HCC cells to release damage-associated molecular patterns (high mobility group box 1 protein and ATP) and cytokines including macrophage colony stimulating factor and type I interferons, improving monocyte differentiation into classically activated macrophages (M1) and dendritic cells. Meanwhile, the VG-sHDLs kill M2 without significant toxicity to M1. After intravenous injection, the VG-sHDLs increase intratumoral M1 as well as proinflammatory molecules such as C-X-C motif ligand 9 and 10 and interleukin 12, but reduce M2 and anti-inflammatory cytokine interleukin 10. These changes enhance the recruitment and activity of cytotoxic T lymphocytes, which eradicate HCC tumors and also establish tumor-specific immune memory that prevents recurrence. This work sheds light on the interactions between sHDL and intratumoral cells, and provides rationale for chemoimmunotherapy of HCC using conventional chemotherapeutics and emerging immune modulators.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Immune cells in cancer · Ferroptosis and cancer prognosis · Cancer, Lipids, and Metabolism
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (59)
Show source-provided references
1. Cancer immunotherapy using checkpoint blockade10.1126/science.aar4060 ↗
2. Understanding the tumor immune microenvironment (TIME) for effective therapy10.1038/s41591-018-0014-x ↗
3. Nanomedicine for tumor microenvironment modulation and cancer treatment enhancement10.1016/j.nantod.2018.06.008 ↗
4. Recent advances in nanosized drug delivery systems for overcoming the barriers to anti-PD immunotherapy of cancer10.1016/j.nantod.2019.100801 ↗
5. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
6. Non-cell-autonomous tumor suppression by p5310.1016/j.cell.2013.03.020 ↗
7. Fibrosis-dependent mechanisms of hepatocarcinogenesis10.1002/hep.25670 ↗
8. Alternatively activated (M2) macrophages promote tumour growth and invasiveness in hepatocellular carcinoma10.1016/j.jhep.2014.10.029 ↗
9. Tumor-associated macrophages: from mechanisms to therapy10.1016/j.immuni.2014.06.010 ↗
10. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial10.1200/JCO.19.01307 ↗
11. HDL cholesterol efflux capacity and incident cardiovascular events10.1056/NEJMoa1409065 ↗
12. Tailoring nanomaterials for targeting tumor‐associated macrophages10.1002/adma.201808303 ↗
13. Progress on modulating tumor‐associated macrophages with biomaterials10.1002/adma.201902007 ↗
14. Tumour microenvironment responsive nanoconstructs for cancer theranostic10.1016/j.nantod.2019.03.007 ↗
15. Functional T cell activation by smart nanosystems for effective cancer immunotherapy10.1016/j.nantod.2019.05.004 ↗
16. Tumor microenvironment-responsive intelligent nanoplatforms for cancer theranostics10.1016/j.nantod.2020.100851 ↗
17. Designing inorganic nanomaterials for vaccines and immunotherapies10.1016/j.nantod.2019.04.005 ↗
18. Engineered nanomedicines with enhanced tumor penetration10.1016/j.nantod.2019.100800 ↗
19. Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues10.1038/nnano.2016.168 ↗
20. Iron chelated melanin-like nanoparticles for tumor-associated macrophage repolarization and cancer therapy10.1016/j.biomaterials.2019.119515 ↗
21. Multifunctional nanoregulator reshapes immune microenvironment and enhances immune memory for tumor immunotherapy10.1002/advs.201900037 ↗
22. Spatial targeting of tumor-associated macrophages and tumor cells with a pH-sensitive cluster nanocarrier for cancer chemoimmunotherapy10.1021/acs.nanolett.7b01193 ↗
23. Reprogramming tumor-associated macrophages by nanoparticle-based reactive oxygen species photogeneration10.1021/acs.nanolett.8b03568 ↗
24. Tumor associated macrophage-targeted microRNA delivery with dual-responsive polypeptide nanovectors for anti-cancer therapy10.1016/j.biomaterials.2017.04.043 ↗
25. TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy10.1038/s41551-018-0236-8 ↗
26. Tumors and their microenvironment dual‐targeting chemotherapy with local immune adjuvant therapy for effective antitumor immunity against breast cancer10.1002/advs.201801868 ↗
27. Molecular-targeted immunotherapeutic strategy for melanomaviadual-targeting nanoparticles delivering small interfering RNA to tumor-associated macrophages10.1021/acsnano.7b05465 ↗
28. CSF1R‐ and SHP2‐inhibitor‐loaded nanoparticles enhance cytotoxic activity and phagocytosis in tumor‐associated macrophages
29. High-density lipoprotein nanobiologics for precision medicine10.1021/acs.accounts.7b00339 ↗
30. Nanomedicines for endothelial disorders10.1016/j.nantod.2015.11.009 ↗
31. Cholesterol, inflammation and innate immunity10.1038/nri3793 ↗
32. High-density lipoproteins exert pro-inflammatory effects on macrophages via passive cholesterol depletion and PKC-NF-κB/STAT1-IRF1 signaling10.1016/j.cmet.2016.10.013 ↗
33. SR-B1: a unique multifunctional receptor for cholesterol influx and efflux10.1146/annurev-physiol-021317-121550 ↗
34. Immune cell screening of a nanoparticle library improves atherosclerosis therapy10.1073/pnas.1609629113 ↗
35. Inhibiting inflammation with myeloid cell-specific nanobiologics promotes organ transplant acceptance10.1016/j.immuni.2018.09.008 ↗
36. Designer vaccine nanodiscs for personalized cancer immunotherapy10.1038/nmat4822 ↗
37. Elimination of established tumors with nanodisc-based combination chemoimmunotherapy10.1126/sciadv.aao1736 ↗
38. Chemo-photothermal therapy combination elicits anti-tumor immunity against advanced metastatic cancer10.1038/s41467-018-03473-9 ↗
39. Lipoprotein-inspired nanoparticles for cancer theranostics10.1021/ar200017e ↗
40. Lipoprotein-biomimetic nanostructure enables efficient targeting delivery of siRNA to Ras-activated glioblastoma cells via macropinocytosis10.1038/ncomms15144 ↗
41. A PEGylation-free biomimetic porphyrin nanoplatform for personalized cancer theranostics10.1021/acsnano.5b01077 ↗
42. Kadiyala · ACS Nano · 2019 · 13 · 1365
43. High-density lipoproteins: nature’s multifunctional nanoparticles10.1021/acsnano.5b07522 ↗
44. Hepatocellular carcinoma growth retardation and PD-1 blockade therapy potentiation with synthetic high-density lipoprotein10.1021/acs.nanolett.9b01717 ↗
45. Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy10.1038/s41565-018-0342-5 ↗
46. Immunological aspects of cancer chemotherapy10.1038/nri2216 ↗
47. Dual prognostic significance of tumour-associated macrophages in human pancreatic adenocarcinoma treated or untreated with chemotherapy10.1136/gutjnl-2015-309193 ↗
48. Quantifying the ligand-coated nanoparticle delivery to cancer cells in solid tumors10.1021/acsnano.8b03900 ↗
49. Immunological effects of conventional chemotherapy and targeted anticancer agents10.1016/j.ccell.2015.10.012 ↗
50. HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses10.1038/nature08512 ↗
51. C1q and HMGB1 reciprocally regulate human macrophage polarization10.1182/blood-2016-05-719757 ↗
52. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus10.1126/science.1064890 ↗
53. Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-Pbl-scid mice10.1084/jem.191.10.1777 ↗
54. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm10.1038/ni.1937 ↗
55. Macrophage-released pyrimidines inhibit gemcitabine therapy in pancreatic cancer10.1016/j.cmet.2019.02.001 ↗
56. Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti–PD-1 treatment10.1073/pnas.1720948115 ↗
57. Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells10.1016/j.ccell.2014.09.006 ↗
58. Antitumor activity of a systemic STING-activating non-nucleotide cGAMP mimetic10.1126/science.abb4255 ↗
59. An orally available non-nucleotide STING agonist with antitumor activity10.1126/science.aba6098 ↗